TOP - Other published on September 23, 2010
Wayne Kuznar

CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented by New York researchers.

As such, “naproxen…should be considered for patients beginning pegfilgrastim, providing there are no contraindications,” concluded principal investigator Jeffrey J. Kirshner, MD, director of research and the Community Clinical Oncology Program, Hem atology-Oncology Associates of Central New York, East Syracuse. “However, a significant percentage of patients still will experience pegfilgrastim-induced pain, and there is a need to develop even more effective preventive treatments.”

By stimulating bone marrow production of neutrophils, pegfilgrastim, an immunostimulator, functions as a pegylated granulocyte colony-stimulating factor. It is indicated for reducing the risk of infection in patients with certain types of tumors who require strong chemotherapy.

Pegfilgrastim-induced bone pain, however, is a significant clinical problem, which may result in discontinuation of treatment and lead to less effective chemotherapy dosing.

For this randomized, double-blind, placebo-controlled trial, 510 patients from 17 sites were randomized to receive either naproxen (500 mg twice daily) or placebo on the day of pegfilgrastim administration, and for 5 to 8 days thereafter. Eighty-six percent of the patients enrolled were women; 67% of enrollees had breast cancer.

Eligible patients included those with a diagnosis of nonmyeloid malignancy who were scheduled to receive chemotherapy and a first dose of pegfilgrastim on day 2, 3, or 4 of the chemotherapy cycle. Patients could have no history of active or past gastrointestinal bleeding, have no allergies to nonsteroidal antiinflammatory drugs (NSAIDs) or be currently taking NSAIDs or any medication for preexisting chronic pain, or have undergone heart surgery within the previous 6 months.

Patients were asked to record pain duration and severity and were assessed using the University of Rochester Cancer Center Symptom Inventory Assessment. The primary outcome measure was the area under the curve (AUC) for pain during days 1 through 5.

In both the placebo and naproxen groups, pain peaked at approximately 3 days after pegfilgrastim administration. Mean AUC for pain was significantly reduced from 7.71 in the placebo group to 6.04 in the naproxen group (P = .037).

Naproxen was associated with significant reductions in maximum pain (from 3.40 in the placebo group to 2.59 in the naproxen group; P = .005), the overall incidence of pain (from 76.3% to 65.6%, respectively; P = .01), and the duration of pegfilgrastim-induced bone pain (from 2.40 to 1.92 days, respectively; P = .005). A reduction in severe pain, defined as >5 on a 1 to 10 scale, was of borderline significance, with a reduction from 24.5% in the placebo group to 17.6% in the naproxen group (P = .0643).

No significant adverse events occurred in either group. Associations between the incidence, severity, or preventability of pegfilgrastim-induced bone pain and specific risk factors could not be found.

“There was a suggestion that pegfilgrastim-induced pain may be more frequent in African Americans, with an AUC of 12.88 as opposed to 6.48 in the non–African Americans. But there were only 33 African Americans [in this study], so I’m not sure what to make of this,” Kirshner noted.

Related Items
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Lynch Syndrome
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
TOP Web Exclusives published on October 9, 2018 in Multiple Myeloma
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Lynch Syndrome
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
TOP Web Exclusives published on September 11, 2018 in FDA Approvals, News & Updates
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
TOP Web Exclusives published on September 11, 2018 in Side-Effects Management
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
Wayne Kuznar
TOP Web Exclusives published on August 15, 2018 in NCCN News
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
JHOP Web Exclusives published on August 10, 2018 in Immunotherapy
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
Last modified: May 21, 2015